Average Insider

Where insiders trade, we follow

$ADXN
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotΒ–MarieΒ–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Healthcare
Sector
Biotechnology
Industry
Timothy Mark Dyer
CEO
2
Employees
$7.54
Current Price
$4.98M
Market Cap
52W Low$6.51
Current$7.5418.6% above low, 81.4% below high
52W High$12.05

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00---
Sells00--
3 monthsBuys00---
Sells00--
See activity going back 12 months β€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
No insider transactions found

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Mar 9, 2026
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Version: v26.3.29